戻る Agenda
LS49 Introduction for DIA Japan Community
Session Chair(s)
Kazuhiko Ishida, MSc, RPh
Director, Pharmacovigilance
Astellas Pharma Inc., Japan
Speaker(s)
Tomohiko Takahashi
Tomohiko Takahashi
Otsuka Pharmaceutical Co., Ltd., Japan
Associate Manager, Headquarters of Clinical Development
So Miyoshi
So Miyoshi
Pfizer R&D Japan, Japan
Head of Clinical Pharmacology & Bioanalytics
Yoshiyuki Sugimoto, PhD, RPh
Yoshiyuki Sugimoto, PhD, RPh
Abbvie GK, Japan
Medical Affairs Manager, Medical Affairs, Dermatology, Immunology
Keiko Katsui, PhD
Keiko Katsui, PhD
Japan Agency for Medical Research and Development (AMED), Japan
Division of Research Integrity and Social Co-Creation
Noriaki Nagao, MPharm, PMP
Noriaki Nagao, MPharm, PMP
JAPAN TOBACCO INC., Japan
Director, Clinical Development Dept. , Pharmaceutical Division
Kanji Hirai, RPh
Kanji Hirai, RPh
MSD K.K., Japan
Director, Regulatory Policy & Intelligence, Regulatory Affair Area, Japan Dvlpmt
Taro Amagasaki, PhD
Taro Amagasaki, PhD
Novartis Pharma K.K., Japan
Head, Analytics Japan
Kotone Matsuyama, RPh
Kotone Matsuyama, RPh
Nippon Medical School, Japan
Professor, Department of Health Policy and Management